http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
-
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
-
ImmunityBio to Host Investor Day
-
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
-
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
-
ImmunityBio (IBRX) Receives FDA RMAT Designation for ANKTIVA and CAR-NK
-
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapse
-
ImmunityBio (IBRX): FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
-
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
-
ImmunityBio (IBRX) Announces UK MHRA Accepted MAA for ANKTIVA for Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma
-
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle I
-
ImmunityBio (IBRX) Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
-
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
-
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer C
-
ImmunityBio (IBRX) Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency (earlier)
-
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
-
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
-
ImmunityBio (IBRX) Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
-
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
-
ImmunityBio (IBRX) and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
-
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment
-
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Rang
-
ImmunityBio Reports Third-Quarter 2024 Financial Results
-
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
-
ImmunityBio to Participate in the Jefferies London Healthcare Conference
-
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
-
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
-
Faraday Future Announces Chief Accounting Officer and Interim Chief Financial Officer, and Funding Progress
-
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
